Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori

Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin

(2017) Shoko Ono et al.   HELICOBACTER

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori : A multicenter, prospective, randomized trial

(2017) Soichiro Sue et al.   HELICOBACTER

Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?

(2017) Shou Quan Dong et al.   HELICOBACTER

The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication

(2017) Soichiro Sue et al.   INTERNAL MEDICINE

First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin

(2017) Soichiro Sue et al.   Gastroenterology Research and Practice

Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis

(2016) Yi-Chia Lee et al.   GASTROENTEROLOGY

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection withHelicobacter pyloriin Japan

(2016) Mitsushige Sugimoto et al.   HELICOBACTER

Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen

(2016) Yoshihiro Hirata et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

(2016) Jyh-Ming Liou et al.   LANCET

Letter: sitafloxacin forH. pyloriinfection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm - author's reply

(2015) M. Sugimoto   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies forHelicobacter pyloriStrains Containing thegyrAMutation

(2015) Hideki Mori et al.   HELICOBACTER

The fight against gastric cancer – the IARC Working Group report

(2014) Rolando Herrero et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Comparative study of esomeprazole and lansoprazole in triple therapy for eradication ofHelicobacter pyloriin Japan

(2014) Tsutomu Nishida   WORLD JOURNAL OF GASTROENTEROLOGY

Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan

(2013) Kazunari Murakami et al.   JOURNAL OF GASTROENTEROLOGY

Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan

(2013) Masahiro Asaka et al.   JOURNAL OF GASTROENTEROLOGY

Sitafloxacin-based third-line rescue regimens forHelicobacter pyloriinfection in Japan

(2013) Takahisa Furuta et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

An Easily Accessible Web-Based Minimization Random Allocation System for Clinical Trials

(2013) Lan Xiao et al.   JOURNAL OF MEDICAL INTERNET RESEARCH

Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan

(2012) Yoshihiro Hirata et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Characterization and usefulness of stool antigen tests using a monoclonal antibody to Helicobacter pylori catalase

(2012) Masami Sato et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies

(2011) Juntaro Matsuzaki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Helicobacter pylori treatment in the era of increasing antibiotic resistance

(2010) D. Y. Graham et al.   GUT

Sitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations

(2009) K. Murakami et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH

(2008) Julia Kirchheiner et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology